CT-0508 Demonstrates Cytotoxicity in Solid Tumors


Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

CT-0508, Carisma Therapeutics’ chimeric antigen receptor macrophage (CAR-M) therapy demonstrated safety, feasibility, and clinical validation of its mechanism of action in HER2-overexpressing solid tumors in updated data from a phase 1, first-in-human study (NCT04660929).1

These data were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, by Kim A. Reiss Binder, MD, assistant professor of medicine, University of Pennsylvania Hospital.1

“In preclinical studies, CAR-M phagocytose tumor cells, activate the tumor microenvironment (TME), recruit T cells, and induce antitumor T cell immunity. CT-0508 is a first-in-class CAR-M, comprised of autologous monocyte derived macrophages expressing an anti-HER2 CAR,” Reiss said during her presentation.1

The trial has dosed 9 participants with breast (n = 4), esophageal (n = 2), choloangiocarcinoma (n = 1), ovarian (n = 1), and salivary carcinoma (n = 1) cancer. Participants had a median age of 58 years (range, 45-73); 3 (33.3%) were male, and all were White. Participants had a median of 3 prior therapies (range, 2-11) and a median of 2 prior anti-HER2 therapies (range, 0-9). Five participants (55.6%) had also received prior radiotherapy.

WATCH NOW: Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors

Reiss and colleagues found that CT-0508 was well-tolerated with no dose-limiting toxicities or major organ toxicities. Most adverse events (AEs) were grade 1 or 2, although there were 5 serious AEs that did occur. These included 2 cases of cytokine release syndrome and 1 infusion reaction deemed related to treatment as well as 1 case of gastrointestinal hemorrhage and 1 case of worsening dyspnea related to progressive disease. No AEs led to study discontinuation or CT-0508 dose modification. The investigators also explored preliminary efficacy and determined a best overall response of stable disease in 5 participants (55.6%).

“The data from Group 1 of our first-in-human CAR-M clinical trial provides evidence that CAR-M therapy is feasible and generally well-tolerated by patients with certain late-stage metastatic cancers,” Michael Klichinsky, PharmD, PhD, cofounder and chief scientific officer, Carisma Therapeutics, said in a statement.2 “The translational data collected from these patients is highly encouraging. We look forward to advancing CT-0508 into Group 2 of the monotherapy safety trial, as well as in a combination sub-study with the T cell checkpoint inhibitor pembrolizumab.”

Biomarker studies were also conducted and revealed transient elevations of pro-inflammatory cytokines, which resolved within 48 hours.1 RNAscope technology confirmed rapid migration out of the blood within 4 to 8 hours and into the TME in 8 participants. Biopsies revealed activation of the TME in 6 participants as well as increased T cell clonality. These clones were found to be cytotoxic within the TME.

“CT-0508 led to increased T-cell clonality and significant expansion of newly emergent T cell clones within the TME with concomitant CD8 T cell activation, demonstrating induction of anti-tumor immunity,” Reiss concluded her presentation.1

Click here to view more coverage of the 2022 SITC meeting.

1. Reiss KA, Yuan Y, Ueno NT, et al. A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors.Presented at: SITC 37th Annual Meeting, November 8012, 2022, in Boston, Massachusetts. Poster #634
2. Carisma Therapeutics announces clinical & pre-clinical updates. News release. Carisma Therapeutics. November 11, 2022. https://carismatx.com/carisma-therapeutics-announces-clinical-pre-clinical-updates/
Related Videos
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
Sharif Tabebordbar, PhD, on Improving In Vivo Gene Editing for DMD
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
© 2024 MJH Life Sciences

All rights reserved.